• 1
    Mahdi-Rogers M, Hughes RAC. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2013; 21: 2833.
  • 2
    Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78: 13491353.
  • 3
    Kusumi M, Nakashima K, Nakayama H, Takahashi K. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. Psychiatry Clin Neurosci 1995; 49: 169174.
  • 4
    Lunn MP, Crawford TO, Hughes RA, Griffin JW, Sheikh KA. Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 2002; 125(Pt 4): 904911.
  • 5
    McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46: 910913.
  • 6
    Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8: 157165.
  • 7
    Iijima M, Koike H, Hattori N, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008; 79: 10401043.
  • 8
    Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39: 432438.
  • 9
    Laughlin RS, Dyck PJ, Melton LJ III, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73: 3945.
  • 10
    Cats EA, van der Pol WL, Van den Berg-Vos RM, Wokke JHJ, Franssen H, van den Berg LH. Multifocal motor neuropathy, a population based study in the Netherlands. J Peripher Nerv Syst 2009; 13: 164.
  • 11
    Cats EA, Van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010; 75: 818825.
  • 12
    McCrone P, Chisholm D, Knapp M, et al. Cost−utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003; 10: 687694.
  • 13
    Blackhouse G, Gaebel K, Xie F, et al. Cost−utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 2010; 8: 14.
  • 14
    Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, ed. Measuring Mental Health Needs, 2nd edn. London: Gaskell, 2001: 200224.
  • 15
    EuroQol. EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199208.
  • 16
    Curtis L. Unit Costs of Health and Social Care. Canterbury, UK: Personal Social Services Research Unit, University of Kent, 2007.
  • 17
  • 18
    Department of Health UK. National framework agreement for the supply of immunoglobulins (1 June 2007 to 31 May 2008) reference number: M/PHS/05/4342. 2007.
  • 19
    BNF. British National Formulary, 54 edn. London: BMJ Group and RPS Publishing, 2007.
  • 20
    Weisbrod BA. The evaluation of human capital. J Polit Econ 1961; 69: 425436.
  • 21
    Office of National Statistics. Annual Survey of Hours and Earnings, 2007.
  • 22
    Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results from a UK General Population Survey. York: Centre for Health Economics, University of York, 1995.
  • 23
    Hughes RA, Gorson KC, Cros D, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010; 74: 651657.
  • 24
    RMC trial. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8: 158164.
  • 25
    Slee M, Selvan A, Donaghy M. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007; 69: 16801687.
  • 26
    Kind P, Hardman G, Macran S. UK population norms for EQ-5D, Discussion Paper 172. University of York, 1999.
  • 27
    Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006; 7(Suppl 2): S96S104.
  • 28
    Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 11121118.
  • 29
    Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006; 77: 973976.
  • 30
    Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 2002; 59: 8491.
  • 31
    Dorman PJ, Slattery J, Farrell B, Dennis MS, Sandercock PA. A randomised comparison of the EuroQol and Short Form-36 after stroke. United Kingdom collaborators in the International Stroke Trial. BMJ 1997; 315: 461.